Pfizer Makes Plans For Interchangeable Adalimumab Filing
Company Sees Double-Digit Growth In Biosimilars Business In Q3 FY21
Executive Summary
Pfizer has announced plans to file for an interchangeable biosimilar version of adalimumab in the US, ahead of its expected launch of its already-approved Humira biosimilar Abrilada (adalimumab-afzb) in July 2023. The company saw a jump of 36% in its biosimilars segment in Q3 on the back of recent launches.
You may also be interested in...
Pfizer’s Biosimilars Top $2.3bn In 2021
Pfizer has continued to report growth in its biosimilars segment, with sales up by more than 50% in 2021 to $2.3bn. Meanwhile, a more modest increase has also been seen in the company’s sterile injectables business.
Generics Bulletin Editor’s Picks For Q4 2021
As 2021 drew to a close, there was no shortage of exciting developments for the off-patent industry. Alongside news of a strategic review affecting one of the biggest generics and biosimilars players, Generics Bulletin also held its annual Global Generics & Biosimilars Awards and brought readers fresh and exclusive insights from top industry executives.
Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval
As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.